Universitè De Genève

Electrophoretics Limited

Bayer Intellectual Property Gmbh

University of Geneva

Fundacio Hospital Universitari Vall D'hebron-institut De Recerca

Electrophorectics Limited

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Jean-Charles Sanchez

Denis Francois Hochstrasser

Gerhard Koenig

Oezkan Yalkinoglu

Catherine Gabrielle Zimmerman

Pierre Lescuyer

Elisabeth Guillaume

Laure Allard

Catherine Gabrielle Zimmermann

Odile Carrette

Özkan Yalkinoglu

Willy Vincent Bienvenut

Joan Montaner

Gerhard König

Denis Francois ProfDr Hochstrasser

Odile Carette

Denis François Hochstrasser

Özkan A Yalkinoglu

The invention relates to a combination of biomarkers and their use in brain injury or mild traumatic brain injury (mTBI) detection. The invention also relates to methods of treating the individual diagnosed with a traumatic brain injury (TBI) or a mild traumatic brain injury (mTBI) using such biomarkers.

Markers and their use in brain injury

A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased patients compared to cerebrospinal fluid from healthy donors.

Diagnostic method for brain damage-related disorders

A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.

Biomarkers for diagnosing alzheimer's disease

A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, selected from A-FABP, E-FABP, PGP 9.5, GFAP, Prostaglandin D synthase, Neuromodulin, Neurofilament L, Calcyphosine, RNA binding regulatory subunit, Ubiquitin fusion degradation protein 1 homolog, Nucleoside diphosphate kinase A, Glutathione S tranferase P, Cathepsin D, DJ-1 protein, Peroxiredoxin 5 and Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) in a sample of body fluid taken from the subject.

Stroke is diagnosed in a subject by determining the concentration of at least one polypeptide selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I in a sample of body fluid taken from the subject.

Diagnostic method for stroke

Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for stroke. The invention provides a diagnostic assay for either of these markers, preferably by ELISA using a anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish stroke from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

Diagnostic assay for stroke

Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

Diagnostic assay for transmissible spongiform encephalopathies

Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for stroke. The invention provides a diagnostic assay for either of these markers, preferably by ELISA using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish stroke from AMI requires an assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.

Polypeptides which have been separated by gel electrophoresis can be identified or characterized by a procedure which has two main stages. In the first stage the gel is digested with a polypeptide-cleaving agent such as an enzyme. This produces mainly large fragments which, in the second stage are electroblotted through a hydrophilic membrane on which is immobilized another polypeptide-cleaving reagent such as an enzyme onto a hydrophobic member, typically a membrane, e.g. of PVDF. The resulting fragments, usually peptides, are identified, preferably by MALDI-TOF MS, or a property may be determined, e.g. by interaction with an antibody.

Growing community of inventors

Geneva, Switzerland

Jean-Charles Sanchez